UNSPSC 51182015: Cloxotestosterone

This classification denotes an anabolic steroid with the molecular formula C21H29Cl3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8422DH508N, chemically known as 17 beta-(2,2,2-tirchloro-1-hydroxyethoxy)androst-4-en-3-one. but generally known as cloxotestosterone, which bears US NIH Compound Identifier 194706. European Medicines Agency schedules Cloxotestosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06785MIG. The term CLOXOTESTOSTERONE is an International Non-Proprietary Name.

UNSPSC 51182015 Cloxotestosterone is a Commodity code covering anabolic steroid pharmaceuticals procured by state and local health systems, correctional facilities, and cooperative purchasing organizations. Based on recent solicitation activity, state and local bodies are acquiring generic multi-source pharmaceutical products through established wholesale distribution channels, requiring vendors to meet stringent manufacturing compliance standards including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certification. Issuing bodies include state health departments and multistate cooperative purchasing alliances that aggregate demand across multiple member jurisdictions and participating facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent buyer, leveraging cooperative purchasing to standardize procurement across state and local members in multiple states including Oregon.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and submit detailed National Drug Code, SKU, UPC, and manufacturing location information in designated CSV format through the ePro system. Award will be effective July 1, 2026, under a two-year initial term with optional extensions. Pricing is weighted at 75 percent of the evaluation, with competitive pricing structures including flat price, net price formats, and WAC-minus options; vendors must maintain commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million. No specific dollar value or set-aside designations appear in the available documentation; all products must possess FDA approval and a minimum six-month shelf life from manufacture date.